DelveInsight’s “Medulloblastoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Medulloblastoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Medulloblastoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Medulloblastoma: An Overview
Medulloblastoma is classified as a primitive neuroectodermal tumour, typically occurring in the cerebellar vermis located in the skull’s posterior fossa. This tumour accounts for 40% of those arising from the posterior fossa.
The recent World Health Organization classification of central nervous system tumors includes the following histologic types of medulloblastoma; classic medulloblastoma, desmoplastic/nodular medulloblastoma, medulloblastoma with excessive nodularity, anaplastic medulloblastoma, and large cell Medulloblastoma.
Medulloblastoma Market Key Facts
-
According to Orphanet, Medulloblastoma (MB) is the most common malignant brain tumor in childhood. Annual incidence varies according to age a group, and is estimated in the USA at 0.47/100,000 in children (0-14 years of age), 0.11/100,000 in adolescents and young adults, 0.02/100,000 in adults (over 40 years of age).
-
Analysis of data from the English national cancer registry for all patients diagnosed with Medulloblastoma during 2001–2015, in England demonstrated the overall average crude incidence rate as 0.12 per 100,000 (2001–2015), with no significant trend between 5-year periods. However, the incidence rate for the age groups 0–3 and 4–14 was significantly higher than the older age groups. Male incidence was significantly higher than female (Khann et al., 2018)
-
According to DelveInsight’s analysis, Medulloblastoma is more common in males, affecting approximately 1.7 times more males than females.
Medulloblastoma Market Size is anticipated to increase during the forecast period owing to the rising awareness among people regarding cancer and its treatment option.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Medulloblastoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Medulloblastoma market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Medulloblastoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Medulloblastoma Epidemiology Segmentation
-
Total Incident cases of Medulloblastoma
-
Age-specific cases of Medulloblastoma
-
Gender-specific cases of Medulloblastoma
Medulloblastoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Medulloblastoma market or expected to get launched during the study period. The analysis covers Medulloblastoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Medulloblastoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/medulloblastoma-market
Medulloblastoma Therapeutics Analysis
The current emerging landscape is limited for Medulloblastoma, mainly comprising of Phase II and Phase I candidate drugs. However, during upcoming periods, many pharma players are likely to expand their pipeline for Medulloblastoma owing to extensive research on the effects of the crosstalk of intersecting pathways on Medulloblastoma tumorigenesis.
Some of the key companies in the Medulloblastoma Market include:
-
Bayer
-
Celegene
-
Bristol-Myers Squibb
-
Y-mAbs Therapeutics
-
Eli Lilly and Company
And others
Medulloblastoma Therapies covered in the report include:
-
177Lu-omburtamab-DTPA
-
Prexasertib
-
Nifurtimox
-
Pomalidomide
-
Bempegaldesleukin in combination with Nivolumab
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/medulloblastoma-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Medulloblastoma Competitive Intelligence Analysis
4. Medulloblastoma Market Overview at a Glance
5. Medulloblastoma Disease Background and Overview
6. Medulloblastoma Patient Journey
7. Medulloblastoma Epidemiology and Patient Population
8. Medulloblastoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Medulloblastoma Unmet Needs
10. Key Endpoints of Medulloblastoma Treatment
11. Medulloblastoma Marketed Products
12. Medulloblastoma Emerging Therapies
13. Medulloblastoma Seven Major Market Analysis
14. Attribute Analysis
15. Medulloblastoma Market Outlook (7 major markets)
16. Medulloblastoma Access and Reimbursement Overview
17. KOL Views on the Medulloblastoma Market.
18. Medulloblastoma Market Drivers
19. Medulloblastoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/medulloblastoma-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Surgery and Radiation Therapy in Brain Cancer Market
“Surgery and Radiation Therapy in Brain Cancer Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Surgery and Radiation Therapy in Brain Cancer. It also covers the latest breakthroughs, collaboration, latest innovations, emerging products, and key companies working in the Surgery and Radiation Therapy in the Brain Cancer market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/